Prognostic Analysis of 131I Efficacy After Papillary Thyroid Carcinoma Surgery Based on CT Radiomics

被引:1
|
作者
Cao, Huijun [1 ]
Shangguan, Linjue [2 ]
Zhu, Hanlin [3 ]
Hu, Chunfeng [1 ]
Zhang, Tong [1 ]
Han, Zhijiang [4 ]
Wei, Peiying [4 ]
机构
[1] Zhejiang Chinese Med Univ, Sch Clin Med 4, Hangzhou 310053, Peoples R China
[2] Hangzhou Canc Hosp, Hangzhou 310005, Peoples R China
[3] Hangzhou Ninth Peoples Hosp, Dept Radiol, Hangzhou 310012, Peoples R China
[4] Westlake Univ, Affiliated Hangzhou Peoples Hosp 1, Sch Med, 261 Huansha Rd, Hangzhou 310006, Peoples R China
来源
关键词
papillary thyroid carcinoma; Iodine-131; radiomics; predictive model; treatment outcome; STIMULATED THYROGLOBULIN LEVEL; CANCER; IMPACT; TOMOGRAPHY; ABLATION;
D O I
10.1210/clinem/dgae364
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To develop and validate a radiomics-clinical combined model combining preoperative computed tomography (CT) and clinical data from patients with papillary thyroid carcinoma (PTC) to predict the efficacy of initial postoperative I-131 treatment. Methods: A total of 181 patients with PTC who received total thyroidectomy and initial I-131 treatment were divided into training and testing sets (7:3 ratio). Univariate analysis and multivariate logistic regression were used to screen clinical factors affecting the therapeutic response to I-131 treatment and construct a clinical model. Radiomics features extracted from preoperative CT images of PTCs were dimensionally reduced through recursive feature elimination and least absolute shrinkage and selection operator. Logistic regression was used to establish a radiomics model, and a radiomics-clinical combined model was developed by integrating the clinical model. The area under the curve (AUC), sensitivity, and specificity were used to evaluate the prediction performance of each model. Results: Multivariate analysis revealed that pre-I-131 treatment serum thyroglobulin was an independent clinical risk factor affecting the efficacy of initial I-131 treatment (P = .002), and the AUC, sensitivity, and specificity for predicting the efficacy of initial I-131 treatment were 0.895, 0.899, and 0.816, respectively. After dimensionality reduction, 14 key CT radiomics features of PTCs were included. The established radiomics model predicted the efficacy of I-131 treatment in the training and testing sets with AUCs of 0.825 and 0.809, sensitivities of 0.828 and 0.636, and specificities of 0.745 and 0.944, respectively. The combined model improved the AUC, sensitivity, and specificity in both sets. Conclusion: The preoperative CT-based radiomics model can effectively predict the efficacy of initial postoperative I-131 treatment in patients with intermediate- or high-risk PTC, and the radiomics-clinical combined model exhibits better predictive performance.
引用
收藏
页码:3036 / 3045
页数:10
相关论文
共 50 条
  • [31] Tumor Thrombus in the Great Veins from Papillary Carcinoma of the Thyroid: 131I Scan Findings
    Mugunthan, Nadarajah
    Kumar, Aravind Ravi
    Thomas, Paul
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2527 - 2528
  • [32] SPECT/CT, 131I, and Lingual Thyroid Ectopia
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (05) : 21N - 21N
  • [33] 131I-SPECT/CT Found an Ovarian Metastasis Covered by Iliac Metastasis on 131I Whole-Body Scan in a Patient With Papillary Thyroid Carcinoma
    Xu, Yan-Hong
    Huang, Xue-Mei
    Song, Hong-Jun
    Qiu, Zhong-Ling
    Luo, Quan-Yong
    CLINICAL NUCLEAR MEDICINE, 2011, 36 (05) : 363 - 364
  • [34] Incremental Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
    Chen, Libo
    Luo, Quanyong
    Shen, Yan
    Yu, Yongli
    Yuan, Zhibin
    Lu, Hankui
    Zhu, Ruisen
    JOURNAL OF NUCLEAR MEDICINE, 2008, 49 (12) : 1952 - 1957
  • [35] Practical dosimetry of 131I in patients with thyroid carcinoma
    Sisson, JC
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2002, 17 (01) : 101 - 105
  • [36] 131I SPECT-CT imaging in management of differentiated thyroid carcinoma (DTC)
    Sergieva, Sonya
    Robev, Bozhil
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [37] 131I SPECT/CT in the Follow-Up of Patients With Differentiated Thyroid Carcinoma
    Menges, Mareen
    Uder, Michael
    Kuwert, Torsten
    Schmidt, Daniela
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (06) : 555 - 560
  • [38] Impact of 131I SPECT-CT on Nodal Staging of Differentiated Thyroid Carcinoma
    Mhiri, A.
    Meddeb, I.
    Slim, I.
    Elbez, I.
    El Ajmi, W.
    Ben Sellem, D.
    Yeddes, I.
    Letaief, B.
    Ghezaiel, M.
    ben Slimene, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S285 - S285
  • [39] Additional Value of 131I SPECT/CT in the Management of Patients with Differentiated Thyroid Carcinoma
    Marini, I.
    Maussier, M.
    Perotti, G.
    Salvatori, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S72 - S72
  • [40] Lymph node metastasis prediction of postoperative papillary thyroid carcinoma before 131I therapy based on plasma metabolomics
    Shi, Liang
    Yu, Fei
    Li, Shaohua
    Zhang, Chuan
    Ni, Yudan
    Meng, Qingle
    Wang, Feng
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65